Top

Published in:

01-05-2019 | Leukemia | Short Communication

First experience of durable cytoreduction in chronic lymphoid leukemia with ¹⁷⁷Lu-DOTATATE

Authors: Tijana Savovic, John O. Prior, Marie Nicod-Lalonde, Alberic Bressoud, Stéphane Roux, Niklaus Schaefer, Marie Meyer

Published in: Medical Oncology | Issue 5/2019

Abstract

This is the first described case of effective and durable cytoreduction after PRRT with ¹⁷⁷Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRef

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2416–23.CrossRef

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-DOTATATE for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35.CrossRef

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRef

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2124–30.CrossRef

Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med Off Publ Soc Nucl Med. 2013;54:1857–61.

Ferone D, Lombardi G. Colao A [Somatostatin receptors in immune system cells]. Minerva Endocrinol. 2001;26:165–73.PubMed

Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology. 1990;71:480–5.PubMedPubMedCentral

Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995;13(8):2012–5.CrossRef

Title: First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE
Authors: Tijana Savovic
John O. Prior
Marie Nicod-Lalonde
Alberic Bressoud
Stéphane Roux
Niklaus Schaefer
Marie Meyer
Publication date: 01-05-2019
Publisher: Springer US
Keywords: Leukemia
Neuroendocrine Tumor
Published in: Medical Oncology / Issue 5/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1266-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

First experience of durable cytoreduction in chronic lymphoid leukemia with ¹⁷⁷Lu-DOTATATE

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer

Interaction between phytotherapy and oral anticancer agents: prospective study and literature review

In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer

Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control

Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer

Neck management in head and neck squamous cell carcinomas: where do we stand?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page